573 related articles for article (PubMed ID: 1662941)
1. [Therapeutic indications of low molecular weight heparins].
Samama MM; Michaut-Paterno F
Arch Mal Coeur Vaiss; 1991 Nov; 84(11 Suppl):1733-43. PubMed ID: 1662941
[TBL] [Abstract][Full Text] [Related]
2. Low molecular weight heparin: a critical analysis of clinical trials.
Green D; Hirsh J; Heit J; Prins M; Davidson B; Lensing AW
Pharmacol Rev; 1994 Mar; 46(1):89-109. PubMed ID: 8190751
[TBL] [Abstract][Full Text] [Related]
3. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacologic and clinical principles for rational anti-thrombotic preventive treatment with low molecular weight heparin].
Pindur G; Köhler M; Heiden M; Leipnitz C; Rupp KH; Wenzel E
Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir; 1990; ():1149-55. PubMed ID: 1983502
[TBL] [Abstract][Full Text] [Related]
5. Low molecular weight heparin and haemodialysis: neutralization by protaminchloride.
Andrassy K
Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S39-43. PubMed ID: 8180328
[TBL] [Abstract][Full Text] [Related]
6. [The new heparins].
Samama M; Babinet-Berthier A
J Mal Vasc; 1992; 17(2):91-106. PubMed ID: 1319447
[TBL] [Abstract][Full Text] [Related]
7. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
8. Reviparin sodium clivarine: a review of its therapeutic use.
Gore M; Kelkar P; Rege N; Ross C
J Indian Med Assoc; 2004 Oct; 102(10):589-90, 592. PubMed ID: 15887830
[TBL] [Abstract][Full Text] [Related]
9. Low molecular weight heparin therapy: is monitoring needed?
Boneu B
Thromb Haemost; 1994 Sep; 72(3):330-4. PubMed ID: 7855780
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials.
Wein L; Wein S; Haas SJ; Shaw J; Krum H
Arch Intern Med; 2007 Jul; 167(14):1476-86. PubMed ID: 17646601
[TBL] [Abstract][Full Text] [Related]
11. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
12. M118--a rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes.
Kishimoto TK; Qi YW; Long A; Capila I; Sasisekharan R; Guerrero L; Fier I; Roach J; Venkataraman G
Thromb Haemost; 2009 Nov; 102(5):900-6. PubMed ID: 19888526
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
14. Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics.
Agnelli G; Sonaglia F
Haematologica; 2002 Jul; 87(7):757-70. PubMed ID: 12091128
[TBL] [Abstract][Full Text] [Related]
15. Dose response relationships of anticoagulant activities after subcutaneous administration of two low molecular weight heparins in healthy individuals.
Hellstern P; Kiehl R; von Blohn G; Köhler M; Meierhenrich U; Wenzel E
Thromb Haemost; 1986 Oct; 56(2):225-8. PubMed ID: 3810557
[TBL] [Abstract][Full Text] [Related]
16. [Practical use of low molecular weight heparins in angiology].
Plettner JL
J Mal Vasc; 1991; 16(4):398-401. PubMed ID: 1665170
[TBL] [Abstract][Full Text] [Related]
17. Management of venous thromboembolic disease. The impact of low-molecular-weight heparin.
Tapson VF; Hull RD
Clin Chest Med; 1995 Jun; 16(2):281-94. PubMed ID: 7656540
[TBL] [Abstract][Full Text] [Related]
18. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis.
Bratt G; Törnebohm E; Granqvist S; Aberg W; Lockner D
Thromb Haemost; 1985 Dec; 54(4):813-7. PubMed ID: 3911482
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery.
Mismetti P; Laporte S; Darmon JY; Buchmüller A; Decousus H
Br J Surg; 2001 Jul; 88(7):913-30. PubMed ID: 11442521
[TBL] [Abstract][Full Text] [Related]
20. [Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio].
Barata JD; Oliveira C; Bruges M; Gusmão L; Santana A; Ponce P; Simões J; Freire I; Crespo F; da Silva AN
Acta Med Port; 1992 Feb; 5(2):65-70. PubMed ID: 1317657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
